Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease
Journal of Virology · 2025
DOI: 10.1128/jvi.00658-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Juan Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus 3C Proteases, Antiviral Agents, Protease Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proteases are versatile therapeutic targets for a wide variety of human diseases, including cancer, cardiovascular diseases, and infections by viruses, bacteria, and parasites. The main protease (M pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has been one of the major drug targets for the treatment of COVID-19. In this study, a small-molecule covalent inhibitor, H102 , of SARS-CoV-2 M pro was developed from serial structural modifications on a compound previously reported by us to have anti-SARS-CoV-2 activity. H102 exhibited very high potency in SARS-CoV-2 M pro inhibition with IC 50 of 8.8 nM and strongly prevented SARS-CoV-2 replication in VeroE6 cells. The co-crystal structure of H102 bound to M pro determined at 1.50 Å resolution provided a structural mechanism of H102 ’s action and revealed an unusual distortion of the catalytic dyad of the viral enzyme which was caused by the benzyl ring of P2 position of H102 interacting with the side chain of catalytic dyad His41 residue of M pro and pulling His41 side chain away from the other catalytic dyad Cys145 residue. This structural mechanism of H102 is very different from that of other reported covalent M pro inhibitors for which His41 side chain orientation and its close proximity to Cys145 remain unchanged with the binding of a covalent inhibitor. As such, H102 may serve as a biochemical probe for investigating further an unusual mechanism of the viral enzyme’s catalytic dyad disruption and inhibition, and as a prototype distinct from other reported covalent inhibitors for the development of novel antiviral agents. IMPORTANCE A nanomolar potent small-molecule inhibitor, H102 , of SARS-CoV-2 M pro was developed and exhibited strong anti-SARS-CoV-2 infection activity in cells. Co-crystal structure determination of its complex with M pro provided a structural mechanism of H102 ’s action and revealed an interesting structural feature: the benzyl ring at the P2 position of H102 interacts with the reorientated His41 side chain, accompanied by a significant increase of the distance between the catalytic dyad Cys145-His41 residues, which is uncommon in reported covalent inhibitors. Compound H102 may be used as a biochemical probe to further investigate mechanisms of M pro inhibition and potentially different type of lead for developing antiviral agents for treating disease caused by novel coronavirus SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Tsinghua University, Beijing, China.
- Ciechanover Institute of Precision and Regenerative Medicine, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
- State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
- State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Reg…
- InnoHK (Centre for Virology, Vaccinology and Therapeutics), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.
ORCID-Profile: Juan Wang, Xiaohong Sang, Jasper Fuk-Woo Chan, Yan Xu, Jing An, Kwok-Yung Yuen, Jianxun Qi, Ziwei Huang
Zitieren
APA
Wang, J., Sang, X., Zheng, W., Chan, J. F. W., Zhou, J., Xu, Y., Han, P., Feng, Y., Fu, L., Tsang, J. O. L., Yuan, S., Ciechanover, A., An, J., Yuen, K. Y., Qi, J., & Huang, Z. (2025). Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease. Journal of Virology. https://doi.org/10.1128/jvi.00658-25
Vancouver
Wang J, Sang X, Zheng W, Chan JFW, Zhou J, Xu Y, et al. Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease. Journal of Virology. 2025. doi:10.1128/jvi.00658-25
BibTeX
@article{Wang2025,
author = {Wang, Juan and Sang, Xiaohong and Zheng, Wenyan and Chan, Jasper Fuk-Woo and Zhou, Jiao and Xu, Yan and Han, Pu and Feng, Yong and Fu, Lifeng and Tsang, Jessica Oi-Ling and Yuan, Shuofeng and Ciechanover, Aaron and An, Jing and Yuen, Kwok-Yung and Qi, Jianxun and Huang, Ziwei},
title = {Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.00658-25}
}
EUVIMED